Novel vanilloid receptor ligands and their use for producing medicaments

Sulfonylamino-benzene derivatives (A), as pure stereoisomers (particularly enantiomers or diastereomers), racemates or mixtures in any proportions, optionally as salts and/or solvates are new. Sulfonylamino-benzene derivatives of formula (A), as pure stereoisomers (particularly enantiomers or diaste...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	SUNDERMANN, BERND, LEE, JEEWOO, DR, SCHIENE, KLAUS, DE VRY, JEAN, SAUNDERS, DEREK JOHN, FRANK, ROBERT, RYU, HYUNG, CHUL, BAHRENBERG, GREGOR, CHRISTOPH, THOMAS
Format:	Patent
Sprache:	eng ; fre ; ger
Schlagworte:	ACYCLIC OR CARBOCYCLIC COMPOUNDS CHEMISTRY HETEROCYCLIC COMPOUNDS HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Sulfonylamino-benzene derivatives (A), as pure stereoisomers (particularly enantiomers or diastereomers), racemates or mixtures in any proportions, optionally as salts and/or solvates are new. Sulfonylamino-benzene derivatives of formula (A), as pure stereoisomers (particularly enantiomers or diastereomers), racemates or mixtures in any proportions, optionally as salts and/or solvates are new. X : O, S or -NCN; Y : amino, NHR 30>, NR 31>R 32>, or (un)saturated optionally substituted (OS) 1-10C aliphatic group; n : 0-4; R 1>-R 4>H, F, Cl, Br, I, SF 5, nitro, CF 3, CN, amino, OH, SH, CONH 2, SO 2NH 2, CONHOH, COOH, CHO, SO 2OH, NHR 11>, NR 12>R 13>, OR 14>, SR 15>, CONHR 16>, CONR 17>R 18>, SO 2NHR 19>, SO 2NR 20>R 21>, COOR 22>, COR 23>, SOR 24>, SO 2R 24> or (un) saturated OS 1-10C aliphatic group; R 5>R 1>, CF 2Cl, or (un)saturated OS 3-9 membered cycloaliphatic ring, attached via C atom, optionally including 1 or more heteroatoms in the ring; either Q : a group of formula (a)-(g); R 6>, R 7>, R 9>R 1>, CF 2Cl, or OS 6-10 membered aryl, optionally attached via OS 1-6C alkylene, 2-6C alkenylene or 2-6C alkynylene; R 8>R 1>, CF 2Cl, amidino, C(=NH)-NHR 27>, guanidino, or N=C(NHR 28>)(NHR 29>); or (un)saturated OS 3-9 membered cycloaliphatic ring, attached via C atom, optionally including 1 or more heteroatoms in the ring, optionally fused with (un)saturated OS mono- or poly-cyclic ring system and/or attached via OS 1-6C alkylene, 2-6C alkenylene or 2-6C alkynylene; or OS 5-14 membered (hetero)aryl group, optionally fused with (un)saturated OS mono- or poly-cyclic ring system and/or attached via OS 1-6C alkylene, 2-6C alkenylene or 2-6C alkynylene; R 10>SF 5, nitro, CF3, CF2Cl, CN, amino, OH, SH, CONH2, SO2NH2, CONHOH, COOH, CHO, SO 2OH, NHR 11>, NR 12>R 13>, OR 14>, SR 15>, CONHR 16>, CONR 17>R 18>, SO 2NHR 19>, SO 2NR 20>R 21>, COOR 22>, COR 23>, SOR 24>, SO 2R 24>, amidino, C(=NH)-NHR 27>, guanidino, or N=C(NHR 28>)(NHR 29>); or 1-10C (un)saturated aliphatic group (OS by 1-9 T); unsubstituted 2-10C alkenyl or 2-10C alkynyl; or (un)saturated OS 3-9 membered cycloaliphatic ring, attached via C atom, optionally including 1 or more heteroatoms in the ring, optionally fused with (un)saturated OS mono- or poly-cyclic ring system and/or attached via OS 1-6C alkylene; or OS 5-14 membered (hetero)aryl group, optionally fused with (un)saturated OS mono- or poly-cyclic ring system and/or attached via OS 1-6C alkylene; T : CN, nitro, OH, amino, SH, 1-5C alkoxy, 1-5C